Announcing the Accelerated Access Collaborative

Accelerated Access Collaborative (AAC) is bringing together a set of seven innovations for rapid uptake.

More information will be announced in Spring 2019. The seven innovations are:

  • Heartflow - A non-invasive personalized cardiac test that reduces the need for unnecessary procedures
  • Placental growth factor (PIG-F) based testing for suspected pre-eclampsia - tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.
  • PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia - Cost-effective drugs that significantly lower cholesterol.
  • High sensitivity troponin tests for early rule out of myocardial infarction (acute) - Diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.
  • Quantitative faecal immunochemical tests for colorectal cancer - Diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
  • Cladribine (Brand name: Mavenclad) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden.
  • Urolift for lower urinary tract symptoms of benign prostatic hyperplasia.

The AHSN Network teams are working closely on local and national plans for supporting rapid uptake of the AAC innovations. If you live or work in the South West and are interested in the spread and adoption of any of the above innovations, please email us on innovation@swahsn.com.